InvestorsHub Logo
Followers 6
Posts 173
Boards Moderated 0
Alias Born 05/02/2014

Re: None

Sunday, 03/29/2015 10:36:22 AM

Sunday, March 29, 2015 10:36:22 AM

Post# of 144812
“The Nuvilex team presents us with a new tool to employ against the symptoms and invasive properties of this very challenging cancer,” said Daniel D. Von Hoff, M.D., Chief Development Officer of TD2. “Our Pancreatic Cancer Research Team (PCRT) colleagues are enthusiastic to begin clinical trials with this approach

http://globenewswire.com/news-release/2015/01/26/699897/10116902/en/PharmaCyte-Biotech-s-Expanded-Follow-up-Study-on-Malignant-Ascites-Fluid-Accumulation-in-Final-Stages-of-Preparation.html


http://www.td2inc.com/


http://en.wikipedia.org/wiki/Daniel_Von_Hoff
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent PMCB News